Trial Profile
Phase II study of the efficacy of peptide T in HIV-positive individuals with cognitive impairment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peptide T (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 21 Aug 2013 Actual initiation date (Jan 2000) added as reported by ClinicalTrials.gov.
- 21 Aug 2013 Planned patient number is 100 according to ClinicalTrials.gov.
- 21 Aug 2013 Planned end date (Aug 2013) added as reported by ClinicalTrials.gov.